Item 1.01 Entry into a Material Definitive Agreement.

On December 5, 2008, Gilead Sciences Limited (GSL), a wholly-owned subsidiary of Gilead Sciences, Inc. (the Company), entered into an Addendum to Tenofovir Disoproxil Fumarate Manufacturing Supply Agreement (the Addendum) with PharmaChem Technologies (Grand Bahama) Ltd. (PharmaChem). The Addendum amends that certain Tenofovir Disoproxil Fumarate Manufacturing Supply Agreement by and between GSL and PharmaChem dated July 17, 2003 (the Original Agreement, and as amended, the Agreement).

Under the terms of the Addendum, the term of the Agreement was extended and GSL will be obligated to purchase certain minimum quantities of bulk tenofovir disoproxil fumarate, which is an active pharmaceutical ingredient in Truvada® (emtricitabine and tenofovir disoproxil fumarate), Atripla™ (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and Viread® (tenofovir disoproxil fumarate), from PharmaChem through 2012, unless the Agreement is earlier terminated or the parties agree to substitute another product. The Addendum also provides for the purchase by PharmaChem of certain key raw materials required for the manufacturing of tenofovir disoproxil fumarate from GSL.

---

Top of the Form